Research programme: cannabinoid receptor CB1 antagonists - Glenmark Pharmaceuticals
Alternative Names: GRC 10389; GRC 10801Latest Information Update: 16 Jul 2016
At a glance
- Originator Glenmark Pharmaceuticals Ltd
- Class
- Mechanism of Action Cannabinoid receptor CB1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity in India (PO)
- 21 Sep 2007 Data presented at the 43rd Annual Meeting of the European Association for the Study of Diabetes (EASD-2007) added to the Diabetes pharmacodynamics section
- 13 Feb 2006 Preclinical trials in Obesity in India (PO)